Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.
作者信息
Kantarjian Hagop, Thomas Deborah, Wayne Alan S, O'Brien Susan
机构信息
Leukemia Department, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA.
出版信息
J Clin Oncol. 2012 Nov 1;30(31):3876-83. doi: 10.1200/JCO.2012.41.6768. Epub 2012 Aug 13.
Abstract
摘要
相似文献
1
Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.
J Clin Oncol. 2012 Nov 1;30(31):3876-83. doi: 10.1200/JCO.2012.41.6768. Epub 2012 Aug 13.
2
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.
Hematol Oncol Clin North Am. 2009 Oct;23(5):949-71, v. doi: 10.1016/j.hoc.2009.07.005.
3
New antibodies for acute lymphocytic leukemia.
Clin Adv Hematol Oncol. 2014 Aug;12(8):547-9.
4
Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Int J Hematol. 2005 Nov;82(4):312-4. doi: 10.1532/IJH97.NA0504.
5
Novel targets for treatment of adult acute lymphocytic leukemia.
Curr Hematol Malig Rep. 2010 Oct;5(4):207-12. doi: 10.1007/s11899-010-0064-8.
6
Monoclonal antibodies in adult acute lymphoblastic leukemia.
Hematology. 2012 Apr;17 Suppl 1:S52-4. doi: 10.1179/102453312X13336169155538.
7
Rituximab as therapy for acute lymphoblastic leukemia.
Clin Adv Hematol Oncol. 2010 Mar;8(3):168-71.
8
Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission.
Med Pediatr Oncol. 2002 Apr;38(4):300-1. doi: 10.1002/mpo.1335.
9
Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy.
Br J Haematol. 2009 Mar;144(5):794-5. doi: 10.1111/j.1365-2141.2008.07497.x. Epub 2008 Nov 19.
10
[Proteins in haematology].
Ther Umsch. 2011 Nov;68(11):610-7. doi: 10.1024/0040-5930/a000221.
引用本文的文献
1
Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O.
Cancer Sci. 2025 Feb;116(2):453-461. doi: 10.1111/cas.16405. Epub 2024 Nov 21.
2
Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors.
ACS Med Chem Lett. 2023 Apr 17;14(5):606-613. doi: 10.1021/acsmedchemlett.3c00029. eCollection 2023 May 11.
3
Clathrin light chain-conjugated drug delivery for cancer.
Bioeng Transl Med. 2022 Nov 28;8(1):e10273. doi: 10.1002/btm2.10273. eCollection 2023 Jan.
4
The cure of leukemia through the optimist's prism.
Cancer. 2022 Jan 15;128(2):240-259. doi: 10.1002/cncr.33933. Epub 2021 Oct 6.
5
Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
Cancer Res. 2020 Feb 1;80(3):458-470. doi: 10.1158/0008-5472.CAN-18-2932. Epub 2019 Nov 29.
6
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.
Front Oncol. 2019 Sep 19;9:917. doi: 10.3389/fonc.2019.00917. eCollection 2019.
7
Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
J Adv Pract Oncol. 2018 Sep-Oct;9(6):670-676. Epub 2018 Sep 1.
8
Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma.
Cells. 2019 Jan 30;8(2):103. doi: 10.3390/cells8020103.
9
Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country.
J Glob Oncol. 2018 Sep;4:1-12. doi: 10.1200/JGO.17.00014.
10
Treatment of Older Patients with Acute Lymphoblastic Leukaemia.
Drugs Aging. 2018 Jan;35(1):11-26. doi: 10.1007/s40266-017-0503-5.
本文引用的文献
1
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
2
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
Pediatr Blood Cancer. 2015 Jul;62(7):1171-5. doi: 10.1002/pbc.25454. Epub 2015 Mar 2.
3
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15.
4
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
J Clin Oncol. 2012 Aug 1;30(22):2776-82. doi: 10.1200/JCO.2011.39.4403. Epub 2012 Jul 2.
5
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.
Blood. 2012 Aug 30;120(9):1868-76. doi: 10.1182/blood-2011-09-377713. Epub 2012 Mar 22.
6
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
Lancet Oncol. 2012 Apr;13(4):403-11. doi: 10.1016/S1470-2045(11)70386-2. Epub 2012 Feb 21.
7
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485.
8
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Clin Cancer Res. 2011 Oct 15;17(20):6417-27. doi: 10.1158/1078-0432.CCR-11-0486.
9
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Clin Cancer Res. 2011 Oct 15;17(20):6398-405. doi: 10.1158/1078-0432.CCR-11-0487.
10
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
Cancer Res. 2011 Oct 15;71(20):6300-9. doi: 10.1158/0008-5472.CAN-11-1374.
Zotero 插件